penia; sepsis Sepsis remains one of the most common and serious complications of neutropenia, resulting in substantial morbidity and mortality in patients with congenital neutrophil deficiencies and cancer patients undergoing myelosuppressive chemoradiotherapy. Most septic episodes in neutropenic patients may be controlled with the use of broad spectrum antimicrobial therapy and appropriate supportive care, but in a significant number of cases the patient succumbs to overwhelming bacterial or fungal infection. 1, 2 The transfusion of granulocytes to neutropenic recipients represents a logical approach to overcome the deficiency of neutrophils, and therefore prevent the complications of neutropenia. The first attempt at transfusing granulocytes into neutropenic recipients was made in the 1930s when a 'leucocyte cream' was injected intramuscularly in an attempt to stimulate granulopoiesis in the recipient. 3 Subsequently, granulocyte transfusions (GTX) were developed in canine models 4 and were shown to protect animals from bacterial sepsis in a dose-dependent manner. 5 However, despite several randomised studies of GTX in neutropenic patients, no clear benefit for this intervention could be demonstrated 6 and enthusiasm for this practice waned. A major limitation of the GTX employed in these early studies was the small dose of neutrophils that could be obtained using available technology. With the introduction into clinical practice of the recombinant haematopoietic growth factor G-CSF, substantially higher numbers of neutrophils could be mobilised into the peripheral blood and consequently harvested for clinical use. This has led to a resurgence of interest in the use of GTX in the therapy of neutropenic sepsis. This review considers the impact of G-CSF on the mobilisation and harvesting of neutrophils for clinical transfusion purposes and the results of recent studies using these higher dose GTX.
Historical aspects of granulocyte transfusions
With the development of effective cancer chemotherapy in the 1960s therapy-related neutropenia and thrombocytopaenia became common clinical scenarios. A logical approach to these problems was to provide transfusions of platelets and granulocytes in an attempt to overcome the profound cytopaenias. The pioneering studies of the early 1960s employed granulocytes harvested from patients with chronic myeloid leukaemia. 7, 8 These initial studies demonstrated a therapeutic benefit that was dependent on the dose of neutrophils transfused, but also highlighted the risks of CMV infection and infusion related reactions. Spurred on by these initial positive results, investigators explored methods of enhancing the yield of granulocytes resulting in the development of both continuous flow leucopheresis and filtration leucopheresis technology. The efficiency of separation of granulocytes from red blood cells during leucopheresis was improved by the addition of the red cell sedimenting agents pentastarch and hydroxyethylstarch. 9 It was noted that harvest yields could be further enhanced by elevating the donors pre-collection neutrophil count using etiocholanolone 10 and subsequently glucocorticoids. 11 Consequently, yields of up to 10 11 granulocytes could be obtained from donors with CML and 1-3 Â 10 10 granulocytes from healthy glucocorticoid stimulated donors.
This new technology was rapidly applied to the clinical setting, and through the 1970s several controlled studies investigated the role of GTX in the treatment of neutropenic sepsis (reviewed by Strauss, 1993) . Although a benefit could be shown for GTX in some studies, [13] [14] [15] this was not a universal finding. 16, 17 Concerns were also raised about the toxicity of GTX with infusion-related complications being reported, 18 and the recognition that the coadministration of amphotericin led to significant pulmonary adverse events. 19 However, analysis of these early studies allowed some useful observations to be drawn. 6 Firstly, in some of the studies failing to show any benefit for GTX, the granulocytes had been harvested using filtration leucopheresis, a process that was shown to impair the function of granulocytes. 20 It also became apparent that filtration leucopheresis was associated with a high incidence of side effects in the donors and significant infusion-related adverse effects in the recipients. 6, 18 Consequently, filtration leucopheresis was no longer employed. Secondly, as had been suggested in preclinical models 5 and studies employing granulocytes from donors with CML, 7 the dose of granulocytes was important in determining the efficacy of GTX. 6 However, the inconclusive results from controlled studies combined with the development of more effective antimicrobial agents and supportive care strategies led to a diminution in the interest of GTX.
Mobilisation and harvesting of granulocytes in the G-CSF era

Neutrophil mobilisation
The development of the recombinant human myeloid growth factors G-CSF and GM-CSF and the demonstration that they may substantially increase circulating granulocytes has reignited interest in the use of therapeutic GTX. Prior to the introduction of G-CSF, neutrophil mobilisation had been achieved almost exclusively through the administration of glucocorticoids. 21 Glucocorticoids increase the circulating pool of neutrophils by redistributing the marginating fraction to the peripheral blood causing a two-to three-fold increase in circulating neutrophil numbers. 22, 23 In contrast, recombinant human G-CSF promotes the proliferation and differentiation of neutrophil precursors, 24 and when administered to healthy donors leads to an increased release of neutrophils and their precursors from the bone marrow with a consequent increase in the peripheral blood neutrophil count. 25 With doses of G-CSF of between 3 and 10 mg/kg body weight, a 15-fold increase in circulating neutrophil numbers may be achieved. 25 Following the administration of G-CSF there is an initial, transient neutropenia lasting 30 min before the circulating neutrophil count peaks at 12 h. The elevated neutrophil count persists for 24-48 h following a single dose of G-CSF, 22 and may be maintained at elevated levels for at least 2 weeks by repeated administration of G-CSF. 25, 26 A total dose of G-CSF of 300À450 mg given subcutaneously produces maximal neutrophil increments, and further escalation of the dose does not produce additional increments. 22 and superoxide anion production. 28, 30 When G-CSF is combined with glucocorticoid administration to the donor the peripheral blood neutrophil count may be increased further 22, 31 and the neutrophil function maintained. 29 
Neutrophil harvesting
As a consequence of G-CSF mobilisation of granulocytes and continuous flow leucopheresis the mean harvest yield of neutrophils is reliably in excess of 4 Â 10 10 , 12,26,28 which represents a three-to five-fold increase over leucopheresis performed following glucocorticoid administration alone. Repeated daily or alternate day administration of G-CSF enables the harvesting of similar yields of granulocytes over a 14-day period from the same donor. 23, 26, 32, 33 By combining G-CSF and glucocorticoid for mobilisation of neutrophils, the harvest yield may be increased relative to using either agent alone. 22, 34, 35, 36 The results of G-CSF/dexamethasone mobilisation as reported by several groups are summarised in Table 1 . These studies suggest that the Table 1 The results of G-CSF used for the mobilisation and harvesting of granulocytes optimal strategy for neutrophil mobilisation combines both G-CSF at a maximal dose of 450 mg with a glucocorticoid given approximately 12 h prior to the leucopheresis procedure.
Granulocyte storage
Granulocytes demonstrate a high level of spontaneous apoptosis in vitro and consequently a limited duration of viability. 37 The time between granulocyte harvest and transfusion to the recipient is therefore restricted, and it is recommended that the granulocytes are transfused as rapidly as possible 38, 39 causing significant limitations in the application of GTX therapy. Maintenance of granulocyte viability in vitro would be useful in extending the application of this modality of treatment. Recent studies have suggested that G-CSF mobilised granulocytes may maintain functional viability and normal chemotactic responses for up to 24 h in vitro. 30 By reducing the temperature of the stored granulocytes viability may be maintained further. 40 However, the optimal conditions to maintain granulocyte viability in vitro require further study and currently storage of GTX for patients beyond 24 h cannot be recommended.
Adverse effects of granulocyte donation
The toxicity to the donor of granulocyte mobilisation and harvesting appears to be minimal with only mild symptoms of bone pains, aches, fatigue and insomnia reported in most studies (Table 2 ). However, these side effects are common and occur in up to two-thirds of healthy donors following the administration of a single dose of G-CSF. 41 The side effects may be dependent on the dose of G-CSF administered but are readily relieved by simple analgesia. 41 The concomitant use of glucocorticoids may contribute significantly to the incidence of insomnia. Concerns have been raised regarding the use of repeated doses of glucocorticoids and the risk of posterior subcapsular cataracts (PSC). 42 Mild PSCs were observed in four of 11 donors who had received a mean prednisone dose of 1260 mg over 4-12 years of granulocyte donation. The risk to donors who receive a much lower dose of steroid are likely to be less, but this finding clearly requires further study. To date, there are no reported long-term adverse consequences of the administration of G-CSF alone to healthy donors. 43, 44 Donor assessment and selection Traditionally, relatives and close friends of patients have been recruited as granulocyte donors, but as discussed below community-based unrelated donors may also be employed. 34, 45 Our experience is that the recruitment of donors presents significant resource and staffing implications. Each donor requires prior counselling, informed consent, medical assessment and virological screening ( Table 3 ). The donor must be ABO and ideally CMV compatible with the recipient, which may potentially limit the availability of suitable donors if daily GTX are required. Most centres will only administer GTX to CMV seronegative recipients from CMV seronegative donors. The need for this practice has been questioned recently as CMV unscreened GTX have not been associated with a higher incidence of CMV reactivation or disease in some studies. 46, 47 However, this practice remains controversial 48, 49 and until further information becomes available, the practice of attempting to provide CMV negative GTX to CMV seronegative recipients is recommended. As discussed below, the impact of leucocyte compatibility testing in determining the outcome of GTX remains unclear. Leucocyte compatibility data should however be collected as part of prospective studies to determine the value of this investigation in the prediction of neutrophil increments and the adverse effects of GTX. It is recommended that clinicians should avoid the use of family members as GTX donors for patients who may be eligible for a sibling allogeneic bone marrow transplant given the risks of allosensitisation.
Clinical results employing G-CSF mobilised granulocytes
Several groups have reported the results of G-CSF stimulated GTX in the treatment of antibiotic-resistant neutropenic sepsis, 28,31,34,45,50-52 sepsis in paediatric patients 53, 54 and as a prophylactic measure in patients undergoing cytoreductive chemotherapy. 32, 33, [55] [56] [57] What can be concluded from these recent studies that have employed G-CSF mobilised granulocytes?
Neutrophil increments in recipients
Firstly, by administering G-CSF-stimulated granulocytes measurable increments in the neutrophil count of up to and that elevated counts may persist for at least 24 h. 26, 34, 50, 57 The increment achieved with each GTX shows some variability and the factors influencing the increments achieved are not clearly established. Surprisingly, in some studies, there was no clear correlation between the dose of neutrophils administered (either total dose or adjusted per kg body weight) and the subsequent neutrophil increment. 32, 33, 45 However, studies comparing different mobilisation strategies suggest that higher granulocyte doses lead to greater increments 34, 50 and the increments reported in the paediatric setting have been generally greater. Some of this discrepancy between studies relates to the lack of uniformity in reporting of neutrophil increments with variable time points post infusion or peak increments being used. The observed neutrophil increment may also depend upon the recipients baseline neutrophil count and whether this is stable or fluctuating following myelosuppressive therapy. 32, 33 Leucocyte incompatibility between donor and recipient may also result in lower neutrophil increments. This observation was first made in the pre-G-CSF era 58, 59 in both preclinical 60 and clinical studies. 61 Leucocyte incompatibility may also inhibit the migration of the transfused neutrophils to sites of infection. [62] [63] [64] Leucocyte compatibility may be measured in several ways including HLA class I typing, screening for recipient HLA or granulocyte-specific antibodies or direct donor/recipient leucocyte cross matching. These various methods have been studied for their impact on the outcome of GTX mobilised with agents other than G-CSF, but the results are conflicting. 58, 59, [61] [62] [63] [64] [65] In more recent studies employing G-CSF mobilised GTX, the method of leucocyte compatibility testing have been variable and in some studies either not performed or not reported. 34, 50, 57 The use of a screening lymphocytotoxicity assay prior to the provision of four prophylactic GTX (from the same donor) to patients undergoing autologous stem cell transplantation was found to predict for lower neutrophil increments following the last two GTX. 33 However, these results were of borderline significance and in a study of GTX for neutropenic sepsis leucocyte incompatibility had no impact on granulocyte increments. 45 The impact of leucocyte incompatibility on granulocyte increments following GTX therefore requires further study.
GTX for neutropenic sepsis
Granulocyte transfusions have been most frequently employed in the management of patients with neutropenic sepsis that is unresponsive to conventional antimicrobial therapy. Under normal physiological circumstances, the bone marrow of a healthy adult produces 10 11 granulocytes per day 62 and may substantially increase this output in response to infection. Most centres therefore attempt to provide daily or twice daily 50 GTX recruiting close friends and relatives of the patient as donors. This often leads to logistical problems as it may be difficult to recruit sufficient numbers of donors that are of the appropriate blood group and CMV status. With the cooperation of the local blood transfusion service, the pool of potential donors may be expanded through the use of community-based donors. 34, 45 Using a combination of both patient relatives-and community-based donors, Price et al 45 were able to provide 75% of planned daily GTX to patients with neutropenic sepsis. In a further report from this group, the delay in provision of the first GTX was shorter when community based donors were used and the procedure was found to be highly acceptable to these donors. 34 Community-based GTX programmes administered by blood transfusion services is a promising approach to improve the provision of GTX in the future.
The clinical outcome of patients with neutropenic sepsis treated with G-CSF mobilised GTX is shown in Table 4 . These studies and isolated case reports 66, 67 suggest that G-CSF mobilised GTX may be helpful in treating established sepsis in neutropenic patients. However, most of these reports are single centre phase I/II studies involving small numbers of patients with a variety of haematological Table 4 Reported clinical results using G-CSF mobilised GTX for the treatment of established neutropaenic sepsis disorders, infectious complications and no control group. In contrast, Hubel et al 34 compared the outcome of a large cohort of patients to a control group that were matched for type of infection, number of prior transplants and relapse status. In that study there was a nonsignificant trend to a worse outcome in recipients of GTX irrespective of the source (progressive or fatal course 57.5 vs 55.9 vs 40.3% for recipients of unrelated GTX, related GTX and controls respectively). In a subgroup analysis, the outcome for patients with bacterial sepsis was significantly worse for recipients of GTX. However, for all patients the overall survival and event-free survival at 6 months from the onset of infection was no different between recipients of GTX and controls. It is therefore currently unclear as to whether the provision of daily G-CSF primed GTX for patients with established neutropenic sepsis has any significant clinical impact. Larger appropriately controlled studies will be required to establish the role of GTX in this setting.
Prophylactic granulocyte transfusions
The results from using G-CSF stimulated granulocytes in the face of established infection suggest that even with effective ablation of neutropenia, such infections are frequently too advanced to be controlled by the combination of antimicobial therapy and GTX. An alternative application for GTX is as a prophylactic strategy in patients deemed to be at a high risk for neutropenic sepsis. Such patients may include those undergoing allogeneic stem cell transplantation, patients with a previous history of significant sepsis who are scheduled for further myelosuppressive therapy and patients undergoing remission induction therapy for acute myeloid leukaemia. By administering a planned sequence of granulocyte transfusions during the predictable period of neutropenia that follows chemotherapy, neutropenia and its complications could potentially be avoided. In the pre-G-CSF era several centres had investigated the use of prophylactic granulocyte transfusions but with limited success. [68] [69] [70] [71] [72] As discussed above, a major limitation of these studies was the inadequate dose of granulocytes administered, and in a meta-analysis of eight such controlled studies there was a suggestion that granulocyte dose and leucocyte compatibility were important determinants of efficacy. 73 Several groups have reported the use of prophylactic G-CSF primed GTX in patients undergoing allogeneic stem cell transplantation, 32, 55, 56 autologous stem cell transplantation 33 and patients with a prior history of fungal infection who are receiving an allogeneic bone marrow transplant. 57, 74 The prophylactic GTX have been administered every 2-4 days employing friends and relatives of the recipient. Using such a strategy the number of days of neutropenia may be reduced relative to historical controls although neutropenia (defined as neutrophil count o0.5 Â 10 9 /l) is not entirely prevented. 32, 56 There is also some evidence that the use of prophylactic GTX may reduce the incidence and severity of sepsis with a reduction in the number of days of fever, 55, 57 maximum CRP levels 56 and antibiotic usage. 55 Although currently reported in abstract form only the Washington University group have conducted a controlled trial where patients undergoing allogeneic stem transplantation were biologically randomised to receive two prophylactic GTX from their HLA matched sibling stem cell donor. Patients receiving GTX had a reduction in several markers of infection 55 and an improved overall survival relative to controls. 56 The definitive results of this study are awaited with interest. At our institution we have now employed prophylactic GTX in 22 patients with a previous history of fungal infection (two proven, four probable and 16 possible according to International Concensus Criteria 75 ), who are undergoing allogeneic stem cell transplantation 57 (and Robinson et al unpublished observations). According to this protocol, patients receive pretransplant antifungal therapy and then prophylactic liposomal amphotericin and GTX during the period of neutropenia following conditioning therapy. A median of 4 GTX (range 2-7) per patient at an average dose of 5.95 Â 10 10 (range 0.7-14.6) neutrophils were administered achieving a mean neutrophil increment of 1.5 Â 10 9 /l. Three patients experienced transient progressive radiological abnormalities suggestive of invasive fungal infection, although this subsequently improved in all three patients. There was no other evidence of progressive fungal infection and there have been no deaths attributable to fungal infection. Taken together, these results suggest that prophylactic granulocyte transfusions may be effective in limiting the period of neutropenia following myeloablative chemoradiotherapy and that the complications of neutropenia may be subsequently reduced. It must be emphasised, however, that the published results to date represent preliminary findings and the efficacy of prophylactic GTX requires further study in large well-controlled trials.
Toxicity of GTX in the recipient
A major concern from earlier studies of GTX was the potential for toxicity in the recipient. In the studies reported to date using G-CSF mobilised GTX, infusions to the recipients have been generally well tolerated with infusion-related fever, chills, hives, hypotension and hypoxaemia being the most frequently reported side effects (Table 5 ). In six large series of GTX comprising 1058 GTX Table 5 Adverse events in recipients of GTX to 171 patients, [31] [32] [33] [34] 50, 57 the incidence of febrile reactions varied between 4 and 12.9%. Pulmonary reactions were recorded in 12 of these 171 patients (7%). While most of these were mild consisting of transient hypoxia, reversible bronchospasm or pulmonary oedema one patient died of what was considered a GTX-associated pulmonary reaction. 31 The pathophysiology underlying GTX-associated pulmonary reactions is varied and include anaphylaxis, volume overload, pulmonary neutrophil sequestration and transfusion-associated acute lung injury. 76 There is therefore a need to carefully monitor patients during and after GTX including assessment of arterial oxygenation. In the studies of G-CSF mobilised GTX that have reported leucocyte compatibility data, there was no association between leucocyte incompatibility and the incidence of adverse reactions. 33, 45 This is in contrast to two earlier reports where GTX mobilised with agents other than G-CSF led to a high incidence of alloimmunisation that was associated with adverse reactions to the infusions. 62, 77 Several factors may explain the low incidence of adverse reactions in more recent studies. In many centres, recipients of GTX now receive routine pre-medication, 33, 45 which may prevent many of the minor adverse reactions. The coadministration of GTX and amphotericin was also found to be responsible for significant pulmonary adverse reactions 17 due to the ability of amphotericin to induce neutrophil aggregation. Many centres now avoid this practice and administer amphotericin at least 2 h after GTX administration. 33, 45 Provided that the GTX are irradiated prior to their administration, the risk of transfusion-associated graft-versus-host disease (GVHD) should be negligible. In a single report there was a higher incidence of grade IV GVHD in recipients of irradiated GTX from unrelated donors when compared to matched controls. 34 However, all of these patients had received an allogeneic bone marrow transplant so it is unclear as to whether the GVHD was due to the transplantation of allogeneic stem cells or the infusion of granulocytes. Antigen-presenting cells that contaminate granulocyte harvests may induce alloreactivity between donor and recipient when GTX are administered to recipients of allogeneic stem cell transplants. There is currently limited information on the incidence of both graft rejection and GVHD in this setting and further studies are required.
Future directions
Over the last 10 years the introduction of recombinant G-CSF has led to significant advances in the mobilisation and harvesting of granulocytes for therapeutic purposes. The yield of granulocytes per leucopheresis using modern technology is reliably in excess of 4 Â 10 10 and measurable increments in the recipient's neutrophil count may be achieved. However, several issues remain unresolved (Table 6 ) and in particular the clinical efficacy of G-CSF mobilised GTX in both the treatment and prophylaxis of neutropenic sepsis requires confirmation. Large, adequately powered and well-controlled multicentre trials will have to be performed in both clinical settings in order to confirm the clinical utility of GTX. Ongoing studies in Europe and the United States and a planned prospective multicenter trial supervised by the Transfusion Medicine/Hemostasis Clinical Trial Network (USA) will provide valuable information in this area. In the meantime, GTX should continue to be employed in patients with neutropenic sepsis that is unresponsive to antimicrobial therapy and should be considered as a prophylactic measure in patients with a previous history of fungal infection who are scheduled to undergo myelosuppressive therapy. However, GTX should be used, where possible, within the context of a clinical study. The optimum frequency of GTX administration in both the treatment and prophylaxis of neutropenic sepsis is also unknown. Until further data is available, we would recommend that daily dosing is used in the treatment of neutropenic sepsis and alternate day dosing for the prophylaxis of infection.
It is also unclear as to the role of leucocyte compatibility in determining the efficacy and toxicity of GTX and the extent of serious pulmonary reactions. There is little data concerning the incidence of alloimmunisation and its consequences in recipients of GTX. These issues will require further systematic study in planned clinical trials. The delivery of regular GTX poses significant logistical difficulties and financial consequences, and these factors must also be considered in future studies. If the efficacy of GTX can be confirmed then local blood transfusion services will have to become actively involved in the recruitment and assessment of donors if adequate supplies of this product are to be provided. There is also an imperative to establish improved methods of granulocyte storage and to determine if adequate numbers of granulocytes can be obtained from alternative sources such as pooled buffy coats. If the clinical efficacy of GTX can be established and progress made in the provision of adequate quantities of this product then GTX therapy will become a routine part of clinical practice. In the setting of allogeneic stem cell transplantation, correction of the predictable neutropenia will become one component of ongoing efforts to accelerate post transplant immune recovery. 
